Androgen blockade enhances response to melanoma vaccine

Journal of Surgical Research

Volumn 110, Issue 2, 2003, Pages 393-398

  Hsueh, Eddy C ^a   Gupta, Rishab K ^a   Lefor, Alan ^b   Reyzin, Gary ^a   Ye, Wei ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Androgen; Flutamide; Immunotherapy; Melanoma

Indexed keywords

ANDROGEN; FLUTAMIDE; GAMMA INTERFERON; INTERLEUKIN 2; MELANOMA VACCINE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL CULTURE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENTAL MODEL; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MELANOMA; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RANDOMIZATION; SPLEEN CELL; TUMOR GROWTH;

EID: 0038547789     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-4804(03)00005-2     Document Type: Article

References (27)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52:2002;23.
2. Morton D.L., Foshag L.J., Hoon D.S.B., Nizze J.A., Famatiga E., Wanek L.A., et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216:1992;463.
3. Morton D.L., Barth A. Vaccine therapy for malignant melanoma. CA Cancer J. Clin. 46:1996;225.
4. Balch C.M., Soong S.J., Shaw H.M., Urist M.M., McCarthy W.H. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. Balch C.M., Houghton A.N., Milton G.W. Cutaneous Melanoma. 1992;180-186 J. B. Lippincott Co, Philadelphia.
5. Sirott M.N., Bajorin D.F., Wong G.Y.C., Tao Y., Chapman P.B., Templeton M.A., et al. Prognostic factors in patients with metastatic malignant melanoma. Cancer. 72:1993;3091.
6. Garbe C., Buttner P., Bertz J., Burg G., d'Hoedt B., Drepper H., et al. Primary cutaneous melanoma Identification of prognostic groups and estimation of individual prognosis for 5093 patients . Cancer. 75:1995;2484.
7. Schuchter L., Schultz D.J., Synnestvedt M., Trock B.J., Guerry D., Elder D.E., et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann. Intern. Med. 125:1996;369.
8. Eton O., Legha S.S., Moon T.E., Buzaid A.C., Papadopoulos N.E., Plager C., et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16:1998;1103.
9. Hsueh E.C., Gupta R.K., Qi K., Morton D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 16:1998;2913.
10. Hsueh E.C., Famatiga E., Gupta R.K., Qi K., Morton D.L. Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax) Correlation with survival . Ann. Surg. Oncol. 7:1998;595.
11. Livingston P., Zhang S., Adluri S., Yao T.J., Graeber L., Ragupathi G., et al. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol. Immunother. 43:1997;324.
12. Grossman C.J. Regulation of the immune system by sex steroids. Endocr. Rev. 5:1984;435.
13. Viselli S.M., Stanziale S., Shults K., Kovacs W.J., Olsen N.J. Castration alters peripheral immune function in normal male mice. Immunology. 84:1995;337.
14. Wilson C.A., Mrose S.A., Thomas D.W. Enhanced production of B lymphocytes after castration. Blood. 85:1995;1535.
15. Smithson G., Beamer W.G., Shultz K.L., Christianson S.W., Shultz L.D., Kincade P.W. Increased B lymphopoiesis in genetically sex steroid-deficient hypogonadal (hpg) mice. J. Exp. Med. 180:1994;717.
16. Smithson G., Couse J.F., Lubahn D.B., Korach K.S., Kincade P.W. The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. J. Immunol. 161:1998;27.
17. Viselli S.M., Reese K.R., Fan J., Kovacs W.J., Olsen N.J. Androgens alter B cell development in normal male mice. Cell Immunol. 182:1997;99.
18. Angele M.K., Wichmann M.W., Ayala A., Cioffi W.G., Chaudry I.H. Testosterone receptor blockade after hemorrhage in males. Arch. Surg. 132:1997;1207.
19. Smyth C.M., Bremner W.J. Klinefelter syndrome. Arch. Intern. Med. 158:1998;1309.
20. Kocar I.H., Yesilova Z., Ozata M., Turan M., Sengul A., Ozdemir I. The effect of testosterone replacement treatment on immunological features of patients with Klinefelter's syndrome. Clin. Exp. Immunol. 121:2000;448.
21. Bizzarro A., Valentini G., Di Martino G., DaPonte A., De Bellis A., Iacono G. Influence of testosterone therapy on clinical and immunological features of autoimmune diseases associated with Klinefelter's syndrome. J. Clin. Endocrinol. Metab. 64:1987;32.
22. Cutolo M., Balleari E., Giusti M., Intra E., Accardo S. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 34:1991;1.
23. Takeda H., Chodak G., Mutchnik S., Nakamoto T., Chang C. Immunohistochemical localization of androgen receptors with mono- and polyclonal antibodies to androgen receptor. J. Endocrinol. 126:1990;17.
24. Danel L., Vincent C., Rousset F., Klein B., Bataille R., Flacher M., et al. Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J. Steroid Biochem. 30:1988;363.
25. Olsen N.J., Kovacs W.J. Gonadal steroids and immunity. Endocr. Rev. 17:1996;369.
26. Stimson W.H., Crilly P.J. Effects of steroids on the secretion of immunoregulatory factors by thymic epithelial cell cultures. Immunology. 44:1981;401.
27. Paavonen T., Andersson L.C., Adlercreutz H. Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures. J. Exp. Med. 154:1981;1935.